John Mendelsohn logo The University of Texas MD Anderson Cancer Center logo

John Mendelsohn

Director, Khalifa Institute for Personalized Cancer Medicine and Past-President, the University of Texas MD Anderson Cancer Center (USA)


I have held leadership positions in cancer centers at University of California San Diego (founding director), Memorial Sloan Kettering Cancer Center (Chairman of Medicine), and MD Anderson (President).  My colleagues and I produced a novel monoclonal antibody against the EGF receptor, cetuximab, which was the first reported agent that prevented activation of a receptor tyrosine kinase and inhibited cell proliferation, and we performed the first clinical trial with a tyrosine kinase inhibitor.  I served as founding editor-in-chief of Clinical Cancer Research and lead editor of the Molecular Basis of Cancer for four editions. 

I am honoured to have been elected the founding chairman of the WIN consortium.  I have been elected to the Institute of Medicine and the American Academy of Arts and Sciences.


Why WIN

“I have been striving to bring targeted cancer into the clinic for more than three decades.  WIN is carrying this goal forward, globally.”

John Mendelsohn logo

John Mendelsohn

Director, Khalifa Institute for Personalized Cancer Medicine and Past-President, the University of Texas MD Anderson Cancer Center (USA)


The University of Texas MD Anderson Cancer Center logo

I have held leadership positions in cancer centers at University of California San Diego (founding director), Memorial Sloan Kettering Cancer Center (Chairman of Medicine), and MD Anderson (President).  My colleagues and I produced a novel monoclonal antibody against the EGF receptor, cetuximab, which was the first reported agent that prevented activation of a receptor tyrosine kinase and inhibited cell proliferation, and we performed the first clinical trial with a tyrosine kinase inhibitor.  I served as founding editor-in-chief of Clinical Cancer Research and lead editor of the Molecular Basis of Cancer for four editions. 

I am honoured to have been elected the founding chairman of the WIN consortium.  I have been elected to the Institute of Medicine and the American Academy of Arts and Sciences.


Why WIN

“I have been striving to bring targeted cancer into the clinic for more than three decades.  WIN is carrying this goal forward, globally.”